bladder cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years, any gender; 2.Pathologically confirmed high-risk NMIBC (HG Ta, T1 ± CIS) post-TURBT with negative resection margins; 3.Tumor subtype confirmed as non-basal by central laboratory review; 4.BCG perfusion therapy was first received and started within 4-6 weeks after TURBT. 5.ECOG performance status 0-1; 6.Adequate hepatic/renal function:(ALT/AST < 2.5 × ULN,Serum creatinine < 1.5 × ULN); 7.Voluntarily signed informed consent with willingness/adherence to protocol requirements (including diet and follow-up).
Exclusion criteria
Exclusion criteria: 1.Radiologically or pathologically confirmed muscle-invasive bladder cancer (>=T2) or metastatic disease; 2.Tumor histology of basal subtype, sarcomatoid differentiation, or neuroendocrine carcinoma; 3.Active tuberculosis, other severe infectious diseases, or contraindications to BCG instillation; 4.Gastrointestinal disorders severely impairing oral intake/nutrient absorption (e.g., complete bowel obstruction, severe Crohn's disease, short bowel syndrome); 5.Documented history of severe allergy to primary components of the prescribed diet (e.g., specific meats, dairy products); 6.Systemic immunosuppressants or high-dose corticosteroids within 4 weeks prior to enrollment; 7.Pregnancy, lactation, or planned pregnancy during the study period; 8.Concurrent participation in other interventional trials that may confound study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rates; | — |
Secondary
| Measure | Time frame |
|---|---|
| Trends in urinary glutamate and serum glutamate levels;Recurrence-Free Survival (RFS) and Progression-Free Survival (PFS);Disease Specific Survival; | — |
Countries
China
Contacts
Yantai Yuhuangding Hospital